4:26 PM
 | 
Nov 10, 2017
 |  BioCentury  |  Finance

Extending Exonics

How TCG is helping gene editing play Exonics transition from virtual to physical

After courting investment offers from several undisclosed VCs and pharmas, gene editing company Exonics Therapeutics Inc. signed on to a $40 million series A from The Column Group because of the VC’s hands-on approach to helping newcos transition from virtual to physical operations.

Exonics debuted in February with a $5 million seed round from CureDuchenne Ventures and CRISPR technology spun out of the lab of scientific founder and Chief Scientific Adviser Eric Olson. Olson is a professor at University of Texas Southwestern Medical Center.

Exonics CEO John...

Read the full 411 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >